SG11201801984TA - Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins - Google Patents

Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Info

Publication number
SG11201801984TA
SG11201801984TA SG11201801984TA SG11201801984TA SG11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA SG 11201801984T A SG11201801984T A SG 11201801984TA
Authority
SG
Singapore
Prior art keywords
type
compositions
methods
chimeric proteins
extracellular domains
Prior art date
Application number
SG11201801984TA
Other languages
English (en)
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Neal SCHILLING
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of SG11201801984TA publication Critical patent/SG11201801984TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201801984TA 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins SG11201801984TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235727P 2015-10-01 2015-10-01
US201562263313P 2015-12-04 2015-12-04
US201662372574P 2016-08-09 2016-08-09
PCT/US2016/054598 WO2017059168A1 (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Publications (1)

Publication Number Publication Date
SG11201801984TA true SG11201801984TA (en) 2018-04-27

Family

ID=58424302

Family Applications (5)

Application Number Title Priority Date Filing Date
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913573UA SG10201913573UA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10201913573UA SG10201913573UA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Country Status (16)

Country Link
US (14) US10183060B2 (enExample)
EP (2) EP4183451B1 (enExample)
JP (3) JP6981973B2 (enExample)
KR (1) KR20180051651A (enExample)
CN (3) CN108350055B (enExample)
AU (3) AU2016331076B2 (enExample)
BR (1) BR112018006578A2 (enExample)
CA (1) CA2999280A1 (enExample)
IL (4) IL295423B2 (enExample)
MX (2) MX389750B (enExample)
PH (1) PH12018500694A1 (enExample)
RU (2) RU2022102624A (enExample)
SA (1) SA518391219B1 (enExample)
SG (5) SG10201913576RA (enExample)
UA (1) UA126549C2 (enExample)
WO (1) WO2017059168A1 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
WO2018127916A1 (en) * 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
HUE057326T2 (hu) 2017-01-05 2022-04-28 Kahr Medical Ltd SIRP1 Alfa-41 BBL fúziós fehérje és eljárások annak alkalmazására
KR102597943B1 (ko) 2017-01-05 2023-11-06 카 메디컬 리미티드 Pd1-41bbl 융합 단백질 및 이의 이용 방법
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CN110290798B (zh) * 2017-02-27 2024-04-05 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
IL313003A (en) * 2017-02-27 2024-07-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
US11267856B2 (en) * 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
EP3600378A4 (en) * 2017-03-24 2020-12-23 Orpheus Bioscience Inc. PANTIDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
KR20180120893A (ko) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도
WO2019023483A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
CN109646678A (zh) * 2017-10-12 2019-04-19 中国科学院上海生命科学研究院 Sun2蛋白、其制药用途及药物
CN108384795A (zh) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 作用于tme免疫效应细胞的人工合成基因及验证方法和应用
US10973878B2 (en) * 2017-10-26 2021-04-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. Recombinant fusion protein containing an anti-PD-L1 antibody
CA3079999A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
US12448415B2 (en) 2018-01-04 2025-10-21 Washington University Compositions and methods for inhibition of alphavirus infection
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
CN111971297A (zh) * 2018-05-16 2020-11-20 韩国亿诺生物有限公司 包含lrit2抑制剂作为活性成分用于预防或治疗癌症的药物组合物
EP3796977A4 (en) * 2018-05-17 2022-03-02 The Board of Trustees of the Leland Stanford Junior University RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT
JP7439372B2 (ja) 2018-06-21 2024-02-28 シャタック ラボ，インコーポレイテッド ヘテロ二量体タンパク質及びその使用
CA3104780A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
CA3104778A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
CN112912384A (zh) * 2018-08-29 2021-06-04 沙塔克实验室有限公司 组合疗法
WO2020047328A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
AU2019328305A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3843755A4 (en) * 2018-08-29 2022-08-31 Shattuck Labs, Inc. FLT3L-BASED CHIMERIC PROTEINS
CN109053902B (zh) * 2018-09-11 2021-06-15 河南科技大学 一种嵌合蛋白aqp4-ch2、制备及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020123477A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
BR112021012027A2 (pt) * 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano
SG11202106895UA (en) * 2019-01-07 2021-07-29 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
JP7663237B2 (ja) * 2019-01-14 2025-04-16 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ がん免疫療法のためのｃｄ２００ａｒリガンド
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
WO2020176718A1 (en) * 2019-02-28 2020-09-03 Shattuck Labs, Inc. Combination therapies
JP2022532430A (ja) * 2019-05-16 2022-07-14 シャタック ラボ，インコーポレイテッド Ｎｋ細胞指向性キメラタンパク質
EP3986442A4 (en) * 2019-06-21 2023-10-25 Shattuck Labs, Inc. Chimeric protein expressing t-cells
WO2021005599A1 (en) * 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
JP2022545439A (ja) * 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
AU2020340424A1 (en) * 2019-08-30 2022-03-31 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
CN110592172B (zh) * 2019-10-29 2021-05-28 华中农业大学 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点
WO2021097278A1 (en) * 2019-11-14 2021-05-20 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN111849913B (zh) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 工程化免疫细胞及其用途
EP4232065A4 (en) * 2020-10-26 2024-10-16 Shattuck Labs, Inc. HOMODIMERIC AND HETERODIMERIC PROTEINS COMPRISING BUTYROPHILIN
EP4237000A4 (en) * 2020-11-02 2024-09-18 Athae Bio, Inc. TWO-DOMAIN MULTIMERIC FUSION PROTEINS
WO2022120187A2 (en) * 2020-12-03 2022-06-09 Shattuck Labs, Inc. Method of determining resistance to checkpoint inhibitor therapies
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
WO2022187583A1 (en) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Combination therapies with tim-3-based chimeric proteins
AU2022229900A1 (en) * 2021-03-05 2023-10-05 Shattuck Labs, Inc. Combination therapies with sirp alpha-based chimeric proteins
KR20220138909A (ko) * 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
US20250092143A1 (en) * 2021-07-23 2025-03-20 University Of Southern California Genetically engineered multifunctional exosomes for immunotherapy
US20240335537A1 (en) * 2021-08-12 2024-10-10 Baylor College Of Medicine Engineered soluble decoy receptors to enhance cancer immunotherapy
EP4453020A4 (en) * 2021-12-23 2025-12-24 Kahr Medical Ltd LILRB POLYPEPTIDES AND THEIR USES
CN118946347A (zh) * 2022-01-20 2024-11-12 埃克索丘尔瑞典公司 表达膜蛋白的重组细胞系及由其制备的囊泡
EP4551692A1 (en) * 2022-07-01 2025-05-14 Fate Therapeutics, Inc. Enhancing effector cell durability and efficacy in adoptive cell therapies
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用
CN120721960B (zh) * 2025-08-19 2025-11-21 上海金域医学检验所有限公司 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632235T2 (de) 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
IL150571A0 (en) 2000-01-03 2003-02-12 Tr Associates L L C Novel chimeric proteins and methods for using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
WO2003042402A2 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003303082B2 (en) * 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
MXPA05012475A (es) * 2003-05-23 2006-05-25 Wyeth Corp Anticuerpos y moleculas relacionadas con el ligando para el receptor tnf inducido por glucorticoides (gitr) y el ligando (gitr) y usos de los mismos.
CN1902227A (zh) * 2003-10-03 2007-01-24 布赖汉姆妇女医院 Tim－3配体及其方法
JP4762904B2 (ja) * 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
CA2568352C (en) * 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007133811A2 (en) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
WO2007149880A2 (en) * 2006-06-21 2007-12-27 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
US20090226435A1 (en) * 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP3605088A1 (en) * 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2729351C (en) 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
EA024877B1 (ru) * 2008-10-02 2016-10-31 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
EA201100947A1 (ru) * 2008-12-19 2012-02-28 Новартис Аг Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
CA2785139A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
SMT201700025T1 (it) * 2011-04-13 2017-03-08 Bristol Myers Squibb Co Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
WO2012162565A2 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
IN2013MN02442A (enExample) * 2011-06-28 2015-06-12 Inhibrx Llc
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
ES2888651T3 (es) 2011-07-29 2022-01-05 Univ Pennsylvania Receptores de conmutación coestimulantes
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
PT3489254T (pt) 2012-04-30 2022-12-30 Biocon Ltd Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico
EP4053162A1 (en) 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2894245C (en) 2012-12-17 2022-03-22 Trillium Therapeutics Inc. Treatment of cd47+ disease cells with sirp alpha-fc fusions
EP2941438A1 (en) 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
AU2014249405C1 (en) 2013-03-12 2018-08-16 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
RS63571B9 (sr) * 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
BR112016008039A2 (pt) * 2013-10-15 2017-10-17 Novo Nordisk Healthcare Ag polipeptídeos do fator vii da coagulação
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
WO2015095410A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2014364606A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
JP6355032B2 (ja) * 2014-03-24 2018-07-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換え二機能性融合タンパク質、それらの調製および使用
US9718870B2 (en) 2014-05-29 2017-08-01 Medimmune, Llc OX40L fusion proteins and uses thereof
WO2015200828A1 (en) 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
TWI702228B (zh) 2014-08-08 2020-08-21 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α（ｓｉｇｎａｌ-ｒｅｇｕｌａｔｏｒｙ ｐｒｏｔｅｉｎ α， ＳＩＲＰ-α）變體構築物及其用途
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
EP3643727A1 (en) 2014-08-15 2020-04-29 Merck Patent GmbH Sirp-alpha immunoglobulin fusion proteins
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES

Also Published As

Publication number Publication date
JP7303254B2 (ja) 2023-07-04
US20180064787A1 (en) 2018-03-08
CN108350055A (zh) 2018-07-31
US10646545B2 (en) 2020-05-12
SG10201913576RA (en) 2020-02-27
US11547742B1 (en) 2023-01-10
EP3356393A1 (en) 2018-08-08
AU2016331076B2 (en) 2020-12-03
US12178847B2 (en) 2024-12-31
US10188701B2 (en) 2019-01-29
US10493128B2 (en) 2019-12-03
JP2023112132A (ja) 2023-08-10
IL316210A (en) 2024-12-01
MX389750B (es) 2025-03-20
AU2024202253A1 (en) 2024-05-16
IL303586B1 (en) 2024-11-01
CN116063566A (zh) 2023-05-05
US10525102B2 (en) 2020-01-07
SA518391219B1 (ar) 2022-11-30
IL295423A (en) 2022-10-01
JP2018529363A (ja) 2018-10-11
IL295423B1 (en) 2023-07-01
EP3356393A4 (en) 2019-08-07
US10449233B2 (en) 2019-10-22
US10660936B2 (en) 2020-05-26
PH12018500694A1 (en) 2018-10-01
US20200101136A1 (en) 2020-04-02
US20250332219A1 (en) 2025-10-30
MX2018004022A (es) 2018-09-11
US11654180B2 (en) 2023-05-23
SG10201913597VA (en) 2020-02-27
WO2017059168A1 (en) 2017-04-06
AU2021200367C1 (en) 2024-05-30
US20170095531A1 (en) 2017-04-06
IL258029B (en) 2022-09-01
US20200246431A1 (en) 2020-08-06
KR20180051651A (ko) 2018-05-16
AU2016331076A1 (en) 2018-04-05
CA2999280A1 (en) 2017-04-06
US20180326007A1 (en) 2018-11-15
BR112018006578A2 (pt) 2018-12-26
IL303586B2 (en) 2025-03-01
CN108350055B (zh) 2022-11-08
US20180326008A1 (en) 2018-11-15
JP6981973B2 (ja) 2021-12-17
EP4183451B1 (en) 2024-11-27
SG10201913573UA (en) 2020-03-30
US20180326006A1 (en) 2018-11-15
US20180125935A1 (en) 2018-05-10
US10086042B2 (en) 2018-10-02
AU2021200367A1 (en) 2021-03-18
RU2022102624A (ru) 2022-03-10
US20180326004A1 (en) 2018-11-15
RU2766200C1 (ru) 2022-02-09
US10653748B2 (en) 2020-05-19
UA126549C2 (uk) 2022-11-02
AU2021200367B2 (en) 2024-05-02
IL258029A (en) 2018-05-31
US10183060B2 (en) 2019-01-22
IL303586A (en) 2023-08-01
EP4183451A1 (en) 2023-05-24
CN116063567A (zh) 2023-05-05
US10543253B2 (en) 2020-01-28
HK1258835A1 (zh) 2019-11-22
JP2021168699A (ja) 2021-10-28
SG10201913591SA (en) 2020-02-27
US20190151413A1 (en) 2019-05-23
MX2022001299A (es) 2022-05-10
IL295423B2 (en) 2023-11-01
US20200261537A1 (en) 2020-08-20
US20180326005A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
IL258029A (en) Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
HUS2400043I1 (hu) VIII-as faktor kimérafehérjék és alkalmazásuk
IL256785A (en) Chimeric polypeptide assembly and methods of making and using the same
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
SG10201914069SA (en) Compositions and methods for tcr reprogramming using fusion proteins
GB201709537D0 (en) Fusion protein comprising three binding domains to 5ta and cd3
ZA201704231B (en) Chimeric protein
PL3240895T3 (pl) Kompozycje i sposoby dla glikozylacji białek
SG11201704010UA (en) Fibroin-derived protein composition
IL247632A0 (en) Methods and compositions for the secretion of heterologous polypeptides
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
IL257302B (en) apoa-1 fusion polypeptides and related compositions and methods
GB201506223D0 (en) Chimeric protein
HK40092182A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
HK40091905A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
HK1259509A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HK1260603A1 (en) Chimeric receptors containing traf-inducing domains and related compositions and methods